Leon Fogelfeld, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Diabetes Transitional Care from Inpatient to Outpatient Setting: Pharmacist Discharge Counseling.
   Shah M, Norwood CA, Farias S, Ibrahim S, Chong PH, Fogelfeld L.
   J Pharm Pract. 2012
   2012 Jul 13. [Epub ahead of print]
   
2. African americans' perception of risk for diabetes complications.
   Calvin D, Quinn L, Dancy B, Park C, Fleming SG, Smith E, Fogelfeld L.
   Diabetes Educ.
   2011 Sep-Oct
   37(5):689-98
   
3. Insulin Injections in Relation to Meals in the Hospital Medicine Ward: Comparison of Two Protocols.
   Guerra YS, Lacuesta EA, Yrastorza R, Miernik J, Shakya N, Fogelfeld L.
   Endocr Pract.
   2011 Mar 31
   1-28
   
4. High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease.
   Rajaram V, Evans AT, Caldito GC, Kelly RF, Fogelfeld L, Black HR, Doukky R.
   Open Cardiovasc Med J.
   2011
   5:188-95
   
5. Computerized physician order entry- based hyperglycemia inpatient protocol and glycemic outcomes: The CPOE-HIP study
   Guerra YS, Das K, Antonopoulos P, Borkowsky S, Fogelfeld L, Gordon MJ, Palal BM, Witsil JC, Lacuesta EA
   Endocr Pract
   2010 May-Jun
   16(3):389-97
   
6. Predictors of diastolic dysfunction among minority patients with newly diagnosed type 2 diabetes
   Kazlauskaite R, Doukky R, Evans A, Margeta B, Ruchi A, Fogelfeld L, Kelly RF
   Diabetes Res Clin Pract
   2010 May
   88(2):189-95
   
7. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes
   Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S
   Diabet Med
   2010 Feb
   27(2):181-8
   
8. Tagatose: from a sweetener to a new diabetic medication?
   Espinosa I, Fogelfeld L
   Expert Opin Investig Drugs
   2010 Feb
   19(2):285-94
   
9. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer
   Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L
   Pituitary
   2010
   13(1):54-9
   
10. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia
    Babu A, Mehta A, Guerrero P, Chen Z, Meyer PM, Koh CK, Roberts R, Schaider J, Fogelfeld L
    Endocr Pract
    2009 Nov-Dec
    15(7):696-704
    
11. Adrenocorticotropic hormone stimulation test during high-dose glucocorticoid therapy
    Villabona CV, Koh C, Panergo J, Reddy A, Fogelfeld L
    Endocr Pract
    2009 Mar
    15(2):122-7
    
12. Implementation, outcomes, and lessons learned from a collaborative primary health care program to improve diabetes care among urban Latino populations.
    McElmurry BJ, McCreary LL, Park CG, Ramos L, Martinez E, Parikh R, Kozik K, Fogelfeld L.
    Health Promot Pract.
    2009 Apr
    10(2):293-302
    
13. Early and later onset type 2 diabetes in uninsured patients: clinical and behavioral differences.
    Smith TL, Drum ML, Miernik J, Fogelfeld LA, Lipton RB.
    J Health Care Poor Underserved.
    2008 Nov
    19(4):1119-35.
    

• To watch a brief video of Leon Fogelfeld, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• Most of the patients that will be referred to me will be mainly to deal with patients that are coming for a second opinion, or for special issues. The special issues might be in the area of complex thyroid problems — especially might come with overactive thyroid, underactive thyroid, presence of nodules in thyroid that there might be that concern that the patient might [be] harboring malignancy in this nodules, or patient that already developed full-blown thyroid cancer and coming to ask questions about the management of this disease.

  Medicine is considered to be [a] very complex field, and it is. But the bottom line of a clinical doctor is that he is a problem fixer. He needs to understand the problem, and then he needs to fix the problem. This is where we need to aspire the most.